In 3-year follow-up of the phase 3 STARGLO trial in transplant-ineligible relapsed/refractory DLBCL, glofitamab plus GemOx vs R-GemOx gave median OS 25.5 vs 12.5 months (HR 0.60) and median PFS 14.4 vs 3.3 months (HR 0.41). No new safety signals.
RCT
Abramson et al. Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO